Workflow
全面预算管控
icon
Search documents
华北制药上半年净利增71.56%,受益于预算管控等措施|财报速递
Sou Hu Cai Jing· 2025-08-13 11:13
Financial Performance - The company's operating revenue for the first half of the year is 5,275,037,790.20, showing a slight increase from 5,231,120,589.63 in the same period last year [1] - Total profit increased to 214,036,244.45 from 150,008,425.67 year-on-year [1] - Net profit attributable to shareholders increased to 123,497,402.89 from 71,984,395.89 year-on-year [1] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose to 119,946,433.69 from 54,349,775.94 year-on-year [1] - Basic earnings per share and diluted earnings per share increased due to improved budget management and cost control measures [1] Cash Flow and Assets - The net cash flow from operating activities decreased to 491,498,056.91 from 883,182,799.92 year-on-year [2] - Net assets attributable to shareholders at the end of the reporting period are 5,467,083,266.95, slightly up from 5,389,402,984.11 at the end of the previous year [1] - Total assets increased to 21,752,942,040.92 from 21,471,458,316.43 year-on-year [1] Non-recurring Gains and Losses - The increase in net profit attributable to shareholders after deducting non-recurring gains and losses is primarily due to a significant reduction in non-recurring gains and losses compared to the same period last year [2]